Acadia Pharmaceuticals
Michelle Mahalin is an experienced professional in drug safety and pharmacovigilance operations. Currently serving as the Director of Drug Safety & Pharmacovigilance Operations at Acadia Pharmaceuticals Inc. since July 2024, Michelle has held several key positions in the field, including Associate Director roles at Sage Therapeutics and TCR² Therapeutics Inc. Previously, Michelle worked at Alexion Pharmaceuticals and Allergan, gaining extensive expertise in global drug safety and patient safety operations. Michelle holds a Master of Science in Nursing from Columbia University School of Nursing, earned between January 2004 and January 2007.
This person is not in any teams
This person is not in any offices